Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec 1;8(12):1836-44.
doi: 10.4161/hv.21909. Epub 2012 Oct 2.

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®

Jun-Yu Wu  1 , Yan Liu, Jiang-Ting Chen, Ming Xia, Xiao-Mei Zhang
Affiliations
Review

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®

Jun-Yu Wu et al. Hum Vaccin Immunother. .

Abstract

In 2002, the first Chinese domestic preservative-free inactivated hepatitis A vaccine, Healive®, was introduced in China. It is highly immunogenic, and provides lasting protection in healthy individuals and generates protective levels of antibodies in other at-risk individuals. Over 10 years since its first licensure, postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. Comparative clinical trials indicated that Healive® induce equal or similar immunogenicity with other currently available inactivated hepatitis A vaccines and are interchangeable for the course of HAV immunization in Chinese children. The vaccine is effective in curbing outbreaks of hepatitis A due to rapid seroconversion and the long incubation period of the disease. Additional issues surrounding the use of the vaccine are also reviewed.

Keywords: Healive®; Hepatitis A; immunogenicity; long-term protection; safety; vaccination.

PubMed Disclaimer

Figures

None
Figure 1. Hepatitis A vaccine distributed by year: 1992–2007. Source: Chinese Domestic Biologic Companies.
None
Figure 2. Marketed and Registration Status of Healive Outside China (Updated on June, 2012).
See this image and copyright information in PMC

References

    1. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines. 2002;1:9–23. doi: 10.1586/14760584.1.1.9. - DOI - PubMed
    1. Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines. 2005;4:459–71. doi: 10.1586/14760584.4.4.459. - DOI - PubMed
    1. Xu ZY, Li ZH, Wang JX, Xiao ZP, Dong DX. Ecology and prevention of a shellfish-associated hepatitis A epidemic in Shanghai, China. Vaccine. 1992;10(Suppl 1):S67–8. doi: 10.1016/0264-410X(92)90547-W. - DOI - PubMed
    1. National Bureau of Statistical of China. China Statistical Yearbook in 2007. China Statistic Press, Beijing, 2008.
    1. Cui F, Hadler SC, Zheng H, Wang F, Zhenhua W, Yuansheng H, et al. Hepatitis A surveillance and vaccine use in China from 1990 through 2007. J Epidemiol. 2009;19:189–95. doi: 10.2188/jea.JE20080087. - DOI - PMC - PubMed

MeSH terms